Ilwoo Park1,2, Adam Elkhaled2, Achuta Kadambi2, Inas Khayal2, Nicholas Butowski3, Susan M. Chang3, Sarah J. Nelson1,2
1Joint Graduate group in Bioengineering, University of California San Francisco/Berkeley, San Francisco, CA, United States; 2Surbeck Laboratory of Advanced Imaging, Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, United States; 3Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, United States
The purpose of this study was to use 3D 1H MR Spectroscopic Imaging (MRSI) and diffusion tensor imaging (DTI) to develop early prognostic markers for GBM patients undergoing radiation, temozolomide and PKC inhibitor. Twenty-nine patients with newly diagnosed GBM were examined using a 3T MR scanner. Conventional anatomical imaging parameters could not distinguish between progression groups at baseline or 1 month. Parameters derived from MRSI and DTI provided information at baseline and early follow-up examinations that may be valuable in predicting the time-to-progression for patients with GBM.